Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
World
Ella Pickover

Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’

Peter Almond finished a trial for donanemab in September (Handout/PA) -

A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be” but fears what happens now he has to stop taking it.

Peter Almond finished a trial for Donanemab in September having been on the drug for three years.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.